uniQure (QURE) CEO sells 206,100 shares and exercises stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
uniQure N.V.’s CEO and Managing Director Matthew C. Kapusta reported a combination of share sales and option exercises in uniQure N.V. ordinary shares. On June 17–18, 2026, he sold an aggregate of 206,100 ordinary shares in multiple open‑market transactions and exercised stock options covering 67,237 ordinary shares.
Sale prices were reported as weighted averages, with underlying trades occurring in ranges disclosed in the footnotes. The filing states these transactions were carried out under a Rule 10b5‑1 sales plan adopted on October 5, 2025. Following the transactions, Kapusta directly owned 521,795 ordinary shares, and the derivative section in this filing shows no remaining stock options related to these exercises.
Positive
- None.
Negative
- None.
Insights
CEO Kapusta executed a pre‑planned sell‑and‑exercise sequence, reducing his stake but retaining a substantial share position.
Matthew Kapusta sold 206,100 uniQure ordinary shares in open‑market trades while exercising stock options for 67,237 shares at strike prices of $19.39 and $31.71. The filing notes these were executed under a Rule 10b5‑1 sales plan adopted on October 5, 2025, indicating the timing was pre‑scheduled rather than opportunistic.
After these transactions, Kapusta directly held 521,795 ordinary shares, showing he maintains a sizable equity position despite the net sale of shares. The derivative section lists no remaining options tied to these specific grants, suggesting a full exercise of the reported awards. Overall, this looks like routine liquidity and option‑exercise management by a senior executive.
Insider Trade Summary 10b5-1
Net Seller: 206,100 shares ($9,371,612)
Net Sell
12 txns
Insider
Kapusta Matthew C
Role
CEO, Managing Director
Sold
206,100 shs ($9.37M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 4,656 | $0.00 | -- |
| Exercise | Ordinary Shares | 4,656 | $31.71 | $148K |
| Sale | Ordinary Shares | 4,656 | $50.00 | $233K |
| Sale | Ordinary Shares | 37,015 | $50.00 | $1.85M |
| Exercise | Stock Option (Right to Buy) | 62,581 | $0.00 | -- |
| Exercise | Ordinary Shares | 62,581 | $19.39 | $1.21M |
| Sale | Ordinary Shares | 23,977 | $42.61 | $1.02M |
| Sale | Ordinary Shares | 6,023 | $43.70 | $263K |
| Sale | Ordinary Shares | 32,581 | $45.02 | $1.47M |
| Sale | Ordinary Shares | 56,929 | $43.43 | $2.47M |
| Sale | Ordinary Shares | 33,334 | $45.01 | $1.50M |
| Sale | Ordinary Shares | 11,585 | $48.65 | $564K |
Holdings After Transaction:
Stock Option (Right to Buy) — 78,706 shares (Direct, null);
Ordinary Shares — 563,466 shares (Direct, null)
Footnotes (1)
- The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.50 to $43.48. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.56 to $43.94. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.02. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.17. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.03. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.01. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The Stock Option vested in full on January 26, 2022. The Stock Option vested in full on January 25, 2023.
Key Figures
Shares sold: 206,100 shares
Options exercised: 67,237 shares
Strike price 1: $19.39/share
+5 more
8 metrics
Shares sold
206,100 shares
Aggregate open-market sales on June 17–18, 2026
Options exercised
67,237 shares
Total underlying ordinary shares from option exercises
Strike price 1
$19.39/share
Exercise price for one stock option grant
Strike price 2
$31.71/share
Exercise price for another stock option grant
Post-transaction holdings
521,795 shares
Ordinary shares directly owned after transactions
Net share change
-206,100 shares
Net buy/sell shares from transaction summary
Option expiration 1
January 26, 2028
Expiration date for $19.39 stock option grant
Option expiration 2
January 25, 2029
Expiration date for $31.71 stock option grant
Key Terms
Rule 10b5-1, weighted average price, Stock Option (Right to Buy), Ordinary Shares, +2 more
6 terms
Rule 10b5-1 regulatory
"intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative exercise/conversion financial
"transaction_action": "derivative exercise/conversion""
FAQ
What did uniQure (QURE) CEO Matthew Kapusta report in this Form 4?
He reported open‑market sales of ordinary shares and exercises of stock options. Across June 17–18, 2026, he sold 206,100 shares and exercised options for 67,237 shares, reflecting routine equity compensation and portfolio management activity.
What stock options did the uniQure (QURE) CEO exercise in this Form 4?
He exercised stock options covering 67,237 ordinary shares. The underlying options carried exercise prices of $19.39 and $31.71 per share, with both option grants reported as having fully vested before these transactions, according to the filing’s footnotes.